IFNG and neoplasm: demonstrated that the accumulation of tumor mutational burden (TMB), upregulation of immune checkpoint genes (e.g., PD-L1), and activation of interferon-gamma (INF-γ) signaling pathways in tumors of elderly patients may synergistically enhance the efficacy of immune checkpoint blockade (ICB) (37).